A clinical trial (NCT03602157) was initiated to ascertain the effectiveness of CAR-T cells co-expressing CD30 and CCR4 in relapsed/refractory CD30+ HL and cutaneous T cell lymphoma (CTCL) (Table 10). This evidence concerns the gene CCR4 and Hodgkins lymphoma.